1,1,1,3-tetranitro-butane | 71706-36-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 原羧酸衍生物
• 英文名称: 1,1,1,3-tetranitro-butane
• 英文别名: 1,1,1,3-Tetranitro-butan；1,1,1,3-Tetranitrobutane；1,1,1,3-tetranitrobutane
• CAS: 71706-36-0
• 化学式: C₄H₆N₄O₈
• 分子量: 238.114
• InChiKey: NMDWJPDBJADFCJ-UHFFFAOYSA-N

物化性质

• 熔点：
  51-52 °C
• 沸点：
  297.7±40.0 °C(Predicted)
• 密度：
  1.629±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  183
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-硝基-1-丙烯 、 三硝基甲烷 在 甲醇 、 水 作用下， 生成 1,1,1,3-tetranitro-butane
  参考文献：
  名称：

  Paranasal Sinus Malignancies: An 18-Year Single Institution Experience

  摘要：

  AbstractObjectives To characterize a single institution experience with management of paranasal sinus malignancies during an 18‐year time period, report long‐term survival rates, and identify prognostic factors.Study Design Retrospective chart review.Methods Studied were 141 patients treated for a paranasal sinus malignancy at a single institution from 1980 to 1997 with a minimum 3‐year follow‐up. Gender, age, TNM stage, anatomic site, pathology, treatment, and recurrence rates were reviewed. Multivariate analysis was performed to determine factors affecting survival.Results The male to female ratio was 1.6:1, and the median patient age was 60 years. Most patients presented with T3/T4 or locally advanced disease (88%), N0 status (96%), and M0 status (96%). The maxillary sinus was the most commonly affected site (70%), followed by the ethmoid sinus (26%). The most common malignancy was squamous cell carcinoma (51%), followed by adenoid cystic carcinoma (12%) and adenocarcinoma (11%). Sixty‐two percent of this study group underwent surgery as part of a multimodality curative treatment plan or alone as curative treatment. Eighteen patients (13%) had unresectable local disease and received non‐surgical palliative treatment. Kaplan‐Meier analysis revealed the 5‐year and 10‐year disease‐specific survival was 52% and 35%, respectively. Multivariate analysis revealed T4 stage (P = .005), N‐positive stage (P = .009), and M‐positive stage (P = .018) negatively impacted survival. Seventy‐two patients (51%) developed recurrent disease at a median time of 336 days after initial treatment.Conclusions Most patients with paranasal sinus malignancies presented with locally advanced disease. Advanced T stage, regional, and distant metastasis are highly predictive of poor survival. Recurrence rate is high and typically occurs within the first year after treatment.

  DOI：

  10.1097/00005537-200211000-00010

文献信息

• Paranasal Sinus Malignancies: An 18-Year Single Institution Experience
  作者：Larry L. Myers、Brian Nussenbaum、Carol R. Bradford、Theodoros N. Teknos、Ramon M. Esclamado、Gregory T. Wolf

  DOI：10.1097/00005537-200211000-00010

  日期：2002.11

  AbstractObjectives To characterize a single institution experience with management of paranasal sinus malignancies during an 18‐year time period, report long‐term survival rates, and identify prognostic factors.Study Design Retrospective chart review.Methods Studied were 141 patients treated for a paranasal sinus malignancy at a single institution from 1980 to 1997 with a minimum 3‐year follow‐up. Gender, age, TNM stage, anatomic site, pathology, treatment, and recurrence rates were reviewed. Multivariate analysis was performed to determine factors affecting survival.Results The male to female ratio was 1.6:1, and the median patient age was 60 years. Most patients presented with T3/T4 or locally advanced disease (88%), N0 status (96%), and M0 status (96%). The maxillary sinus was the most commonly affected site (70%), followed by the ethmoid sinus (26%). The most common malignancy was squamous cell carcinoma (51%), followed by adenoid cystic carcinoma (12%) and adenocarcinoma (11%). Sixty‐two percent of this study group underwent surgery as part of a multimodality curative treatment plan or alone as curative treatment. Eighteen patients (13%) had unresectable local disease and received non‐surgical palliative treatment. Kaplan‐Meier analysis revealed the 5‐year and 10‐year disease‐specific survival was 52% and 35%, respectively. Multivariate analysis revealed T4 stage (P = .005), N‐positive stage (P = .009), and M‐positive stage (P = .018) negatively impacted survival. Seventy‐two patients (51%) developed recurrent disease at a median time of 336 days after initial treatment.Conclusions Most patients with paranasal sinus malignancies presented with locally advanced disease. Advanced T stage, regional, and distant metastasis are highly predictive of poor survival. Recurrence rate is high and typically occurs within the first year after treatment.